IsoRay's Proprietary Cesium-131 Product Line Will Be on Display at the American Society for Radiation Oncology (ASTRO) Convention
Three Private Dinners Will Provide a Forum to Discuss Recently Published Cesium-131 Study Results Involving Brain, Lung, Prostate and Gynecologic Cancers
Marketwired IsoRay, Inc.
October 14, 2015 8:15 AM
RICHLAND, WA--(Marketwired - October 14, 2015) - IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it will host a booth (505) at the 57thAnnual Meeting of the American Society for Radiation Oncology (ASTRO). The annual meeting will take place October 18-21, 2015 in San Antonio, Texas at the Henry B. Gonzalez Convention Center. According to IsoRay CEO Dwight Babcock, "The medical community is becoming increasingly aware of the innovative alternatives that our products offer as an important advance over previous brain, lung, prostate and gynecologic cancer treatments."
IsoRay's Cesium-131 seeds, sutured seeds, stranded mesh and the GliaSite® radiation therapy system give physicians the ability to directly place a specified dosage of radiation in areas where cancer is most likely to remain after tumor removal or when placed directly within the organ. The ability to precisely place a specified dose of radiation means there is less likelihood for damage to occur to healthy tissue compared to other alternative treatments. IsoRay's cancer fighting products diminish the ability of the tumor to recur, providing important benefits for patients in longevity as well as quality of life.
Babcock says "These private dinners provide a forum for peer to peer discussions with other leaders who share their successes in the use of Cesium-131 for some of their most challenging cases. Medical thought leaders recognize the important need for this new powerful weapon in the battle against cancer and Cesium-131 is that solution. A number of new institutions are in the process of licensing Cesium-131 for use within their facility."
IsoRay is the exclusive manufacturer of Cesium-131. The pioneering brachytherapy therapy is one of the most significant advances in internal radiation therapy in 20 years. Cesium-131 allows for the precise treatment of many different cancers because of its unrivaled blend of high energy and its 9.7 day half-life (its unequaled speed in giving off therapeutic radiation).
In addition to its CMS codes, Cesium-131 is FDA-cleared and holds a CE mark for international sales in seed form for the treatment of brain cancer, prostate cancer, lung cancer, ocular melanoma cancer, colorectal cancer, gynecologic cancer, head and neck cancer and other cancers throughout the body. The treatment can be deployed using several delivery methods including single seed applicators, implantable strands and seed sutured mesh, and several new implantable devices including the GliaSite® radiation therapy system.
About IsoRay
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of GliaSite® and Cesium-131 by visiting www.isoray.com. Join us on Facebook/Isoray. Follow us on Twitter @Isoray.
Safe Harbor Statement
Statements in this news release about IsoRay's future expectations, including: the advantages of our products and their delivery systems; future demand for IsoRay's existing and planned products; whether revenue and other financial metrics will improve in future periods, whether IsoRay will be able to continue to expand its base beyond prostate cancer; whether sales and use of our products will continue at historic levels or increase; whether additional medical centers will begin using our products; whether awareness of our products in the medical community will continue or increase; whether our sales and marketing efforts will be successful; whether additional studies will be published or presented with favorable outcomes from treatment with our products; whether we will invest in research and development in the future; and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of IsoRay's products, changing levels of demand for IsoRay's current and proposed future products, IsoRay's ability to reduce or maintain expenses while increasing sales, patient results achieved using our products in both the short and long term, success of future research and development activities, patient results achieved when our products are used for the treatment of cancers and malignant diseases beyond prostate cancer, IsoRay's ability to successfully manufacture, market and sell its products, IsoRay's ability to manufacture its products in sufficient quantities to meet demand within required delivery time periods while meeting its quality control standards, the success of our sales and marketing efforts, IsoRay's ability to enforce its intellectual property rights, changes in reimbursement rates, changes in laws and regulations applicable to our products, whether additional studies and protocols are released and support the conclusions of past studies and protocols, whether ongoing patient results with our products are favorable and in line with the conclusions of clinical studies and initial patient results, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products in their various forms, continued compliance with ISO standards as audited by BSI, and other risks detailed from time to time in IsoRay's reports filed with the SEC. Unless required to do so by law, the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact:
PCG Advisory Group
535 Fifth Avenue
24th Floor
New York, NY 10017
info@pcgadvisory.com
(646)-863-6341
